Study of everyday disease burden in alopecia areata, vitiligo and hidradenitis suppurativa
Looks at how alopecia areata, vitiligo or hidradenitis suppurativa affect teenagers and adults.
Key facts
- Who runs it
- AbbVie
- Where
- Aarau, Basel Town, Bellinzona, Bern, Geneva, Lucerne, Lugano, Orsières, and Zurich, SwitzerlandSee the 10 sitesAlso in 17 other countries, 106 sites
- Trial code
- Registry title
- A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
- Status
- Recruiting
- People taking part
- 2,795 people, planned
- Started
- 2 Sept 2025
- Expected to end
- Aug 2027
- Type of study
- Observational, 3 groups
- Record updated
- 13 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teens and adults with vitiligo, alopecia areata or hidradenitis suppurativa. It is one visit to collect data and questionnaires on how the disease affects daily life.
- Age
- 12 Years and older
- Sex
- All sexes
- Disease stage
- A doctor-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe alopecia areata (AA, patchy hair loss), or moderate to severe hidradenitis suppurativa (HS, painful skin lumps).
Main reasons for not taking part
- Taking part in an interventional clinical trial at the time of the study visit. Other observational studies or registries are allowed.
- Unable or unwilling to follow study requirements or fill in the questionnaires.
- Unable to understand the study questionnaires. Teens may have caregiver help.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
- Participants Ability to understand study questionnaires, with caregiver support as required for adolescents
Who cannot take part
- Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
- Unable or unwilling to comply with study requirements and PRO collection
Where in Switzerland
Also in 17 other countries, 106 sites
- Kantonsspital Aarau /ID# 276810Aarau, SwitzerlandContact: Beth RycroftTaking people
- University Hospital Basel /ID# 276716Basel Town, SwitzerlandContact: Beth RycroftTaking people
- Ospedale Regionale Bellinzona E Valli /ID# 277964Bellinzona, SwitzerlandContact: Beth RycroftTaking people
- Inselspital, Universitaetsspital Bern /ID# 276718Bern, SwitzerlandContact: Beth RycroftTaking people
- Cabinet Dr Damjan Nikolic, Clinique du Seujet /ID# 278467Geneva, SwitzerlandContact: Beth RycroftTaking people
- Hopitaux Universitaires de Geneve /ID# 277950Geneva, SwitzerlandContact: Beth RycroftTaking people
- Luzern Kantonsspital /ID# 276813Lucerne, SwitzerlandContact: Beth RycroftTaking people
- Studio Medico Dr. Pelloni Francesco /ID# 277948Lugano, SwitzerlandContact: Beth RycroftTaking people
- Basile Darbellay SA /ID# 276811Orsières, SwitzerlandContact: Beth RycroftTaking people
- Praxis Dr. med. Pierre de Viragh /ID# 276855Zurich, SwitzerlandContact: Beth RycroftTaking people
About the trial
What the trial wants to find out
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
The 3 groups in the trial
- Participants with Vitiligo
Participants with vitiligo will undergo a single-visit data collection per routine clinical practice
- Participants with Alopecia Areata
Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice
- Participants with Hidradenitis Suppurativa
Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
- Plain-language title
- Study of everyday disease burden in alopecia areata, vitiligo and hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 February 2026